About: Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $24.03 (+2.17%)
ANRO NYSE Alto Neuroscience, Inc.
Alto Neuroscience, Inc. share price
ANRO price activity
Last Price
$24.030
Change (24hr)
0.51 USD (2.17%)
Volume
408.70K
Volume (4w avg)
-
Open
$23.01
Day Range
$22.81 - $24.05
Previous Close
$23.52
Last Trade
08 Oct, 8:00 pm GMT+0
Delayed
08 Oct, 8:00 pm GMT+0
ANRO price performance
Delayed
08 Oct, 8:00 pm GMT+0
ANRO Market Signals